The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 21, 2020

Filed:

Feb. 28, 2019
Applicant:

Magenta Therapeutics, Inc., Cambridge, MA (US);

Inventors:

Andrew Nixon, Hanover, MA (US);

Dwight Morrow, West Chester, PA (US);

Adam Hartigan, Brookline, MA (US);

Assignee:

Magenta Therapeutics, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); C07K 16/28 (2006.01); C12N 5/0789 (2010.01); A61K 39/395 (2006.01); C12N 5/00 (2006.01); A61K 31/4745 (2006.01); A61K 31/5517 (2006.01); A61K 31/704 (2006.01); A61K 35/28 (2015.01); A61K 38/07 (2006.01); A61P 37/06 (2006.01); A61P 35/02 (2006.01); A61K 35/12 (2015.01); A61K 38/12 (2006.01); C07K 14/37 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6817 (2017.08); A61K 31/4745 (2013.01); A61K 31/5517 (2013.01); A61K 31/704 (2013.01); A61K 35/12 (2013.01); A61K 35/28 (2013.01); A61K 38/07 (2013.01); A61K 38/12 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 47/6803 (2017.08); A61K 47/6809 (2017.08); A61K 47/6811 (2017.08); A61K 47/6829 (2017.08); A61K 47/6849 (2017.08); A61K 47/6897 (2017.08); A61P 35/02 (2018.01); A61P 37/06 (2018.01); C07K 14/37 (2013.01); C07K 16/2803 (2013.01); C07K 16/289 (2013.01); C07K 16/2863 (2013.01); C07K 16/2866 (2013.01); C07K 16/2896 (2013.01); C12N 5/0087 (2013.01); C12N 5/0647 (2013.01); A61K 2035/124 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C12N 2501/599 (2013.01);
Abstract

The invention provides compositions and methods useful for the depletion of cells, such as CD45+, CD135+, CD34+, CD90+, and/or CD110+ cells, and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.


Find Patent Forward Citations

Loading…